abstract: Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer

Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer

Conclusion: Managing chemotherapy-induced anemia with biosimilar epoetin α is consistently cost efficient over treatment with originator epoetin α, epoetin β, and darbepoetin α under both fixed and weight-based dosing scenarios.

full free access: Guidelines Loading... American Society of Hematology Guidelines Epoetin and Darbepoetin

Guidelines

American Society of Hematology Guidelines

Epoetin and Darbepoetin
"American Society of Hematology/American Society of Clinical Oncology 2010 clinical practice guideline update on the use of epoetin and darbepoetin"The latest research and evidence-based clinical guidelines about the use of epoetin for the treatment of cancer-related anemia.

• Unabridged Guideline
• Data Supplement 
  
  "Future directions
  There is clear evidence regarding the ability of ESAs to increase
  Hb and avoid transfusions. There is also evidence of harm
  associated with their use. Perhaps the most pressing need for
  additional research is studies that further clarify the mechanisms of
  harm and, particularly, the groups of patients or circumstances of
  clinical use that are least associated with these risks. This understanding
  is paramount to the ability of clinicians to extend the
  benefit of these drugs while reducing the risks."

full free access: American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer — JCO

"Editor's Note: This document represents an abridged version of the complete guideline update and contains updated recommendations with a brief discussion of the relevant literature. Readers should refer to the complete guideline update, which includes a comprehensive discussion and analysis of the literature and more evidence tables. The complete guideline is available at www.asco.org/guidelines/esa and http://www.hematology.org/guidelines/esa/."